Saturday 17 October 2026
Export PSNL’s income statement to Excel — free account
Personalis, Inc.
PSNL Healthcare Diagnostics & Research
Personalis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $69.6 million, down 17.7% from fiscal 2024. In the quarter to June 2026, revenue grew 30.0%, EPS fell 30.4% and free cash flow fell 123.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
15.65
0.28
−1.76%
Follow PSNL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
8.37 | 10.20 | 10.29 | 20.28 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(26.52) | (31.93) | (29.53) | (54.82) | |
P/B ratio |
3.37 | 2.72 | 2.61 | 6.01 | |
Price to Tangible BV |
3.37 | 2.72 | 2.61 | 6.01 | |
EV/Sales |
6.45 | 7.01 | 6.95 | 17.48 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(7.37) | (6.52) | (5.64) | (13.20) | |
EV/FCF |
(6.74) | (6.15) | (5.31) | (12.08) | |
Quick Ratio |
4.56 | 6.46 | 6.31 | 4.91 | |
Current Ratio |
4.82 | 6.76 | 6.61 | 5.28 | |
Net Debt/EBITDA |
6.91 | 10.15 | 7.54 | 6.60 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.29 | 0.23 | 0.22 | 0.24 | |
Operating CF/Net income |
1.01 | 0.93 | 0.75 | 0.81 | |
Capex/Depreciation |
(1.07) | (0.05) | (2.47) | (2.81) | |
Interest Coverage |
(363.92) | (388.71) | (684.28) | (907.86) | |
Research and Development Expense of Revenue |
83.97% | 75.36% | 93.97% | 73.07% | |
Selling, General and Administrative Expense of Revenue |
89.92% | 81.26% | 115.71% | 98.39% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
14.36% | 13.25% | 16.50% | 17.81% | |
Graham Net Nets |
0.18 | 0.27 | 0.28 | 0.12 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(13.50%) | (11.43%) | (16.01%) | (8.13%) | |
Free Cash Flow Yield |
(11.44%) | (11.18%) | (12.74%) | (7.14%) | |
Revenue per Share |
0.16 | 0.19 | 0.15 | 0.21 | |
Operating CF per Share |
(0.25) | (0.25) | (0.22) | (0.24) | |
Capex per Share |
(0.02) | 0.00 | (0.03) | (0.04) | |
Free Cash Flow per Share |
(0.26) | (0.25) | (0.25) | (0.28) | |
Cash per Share |
1.70 | 2.69 | 2.24 | 2.02 | |
Shareholders Equity per Share |
1.93 | 2.93 | 2.45 | 2.23 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.93 | 2.93 | 2.45 | 2.23 | |
Free Cash Flow |
(23.43) | (22.32) | (25.55) | (29.55) | |
Working Capital |
138.25 | 228.32 | 219.15 | 198.67 | |
Capital Expenditures |
(1.63) | (0.08) | (3.07) | (3.78) | |
Net Current Asset Value |
102.98 | 194.97 | 187.57 | 168.08 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.11 | 0.00 | 0.20 | 0.17 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
13.93 | 12.17 | 12.00 | 12.53 | |
Average Payables |
11.80 | 9.69 | 10.30 | 12.97 | |
Average Inventory |
6.57 | 6.04 | 5.93 | 7.54 | |
Average Assets |
241.36 | 302.22 | 299.35 | 285.41 | |
Average Common Equity |
169.09 | 232.07 | 231.06 | 213.00 |
Columns are period end dates